It has been a volatile year for the biotech.

BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.

Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

Allergic reactions after COVID shots appear only in participants with severe allergy and/or mast cell disorder histories, but ...

About BioNTech BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to ...

BioNTech will present Phase 2 clinical trial data on pumitamig combinations for advanced cancers at ESMO 2026.

Healthcare is drawing fresh buying as money moves away from the market’s popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA ...

La Trobe University is now home to one of the world's leading biopharmaceutical companies, with the official opening of BioNTech's state-of-the-art ...

Bank of America cut its BioNTech target from USD 122.00 to USD 114.00 on October 9, 2026, while maintaining a Buy rating, ...

First, a little bit of background. BioNTech partnered with Pfizer(NYSE: PFE) to develop and market Comirnaty, a leading coronavirus vaccine. Even though the biotech was handsomely rewarded for its ...

BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will announce its financial results for the third quarter 2026 on Tuesday, November 3, 2026.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.